Table 1

Patient demographics and disease characteristics at baseline

Etanercept (n=12)Placebo (n=12)
Mean age, years (SD)34.5 (12.4)40.0 (10.4)
Male, n (%)7 (58.33)9 (75.00)
Mean BMI, kg/m2 (SD)26.0 (4.5)25.7 (3.7)
Mean years since first symptom of heel enthesitis (SD)2.5 (1.9)3.3 (3.3)
History or present symptoms of, n (%):
 Axial involvement8 (66.67)7 (58.33)
 Peripheral arthritis10 (83.33)11 (91.67)
 Extra-articular features5 (41.67)3 (25.00)
 HLA-B27 positive, n (%)9 (75.00)8 (66.67)
 Number of different NSAIDs since first symptoms3.58 (2.11)3.00 (1.41)
 Back pain (VAS; 0–100)44.0 (27)52.1 (38)
Disease activity
 PGA (VAS; 0–100)66.0 (17.9)72.9 (15.9)
 Heel pain (VAS; 0–100)64.9 (14.6)71.4 (18.1)
 WOMAC function43.4 (21.6)50.4 (18.2)
  • BMI, body mass index; HLA, human leucocyte antigen; NSAIDs, non-steroidal anti-inflammatory drugs; PGA, patient global assessment; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis index.